Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06292221 · ClinicalTrials.gov registry record · NA

Personalized Depression Treatment Supported by Mobile Sensor Analytics

A NA study of Depression, sponsored by UConn Health.

Completed
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT06292221: Completed NA study of Depression, sponsored by UConn Health.

NCT06292221 is a NA study of Depression that has completed, run by UConn Health. The registered enrollment target is 22 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06292221, a NA study of Depression, has completed, sponsored by UConn Health.

COMPLETED
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The current best practice guidelines for treating depression call for close monitoring of patients, and periodically adjusting treatment as needed. This present study seeks to develop and investigate an innovative digital system, DepWatch, that leverages mobile health technologies and machine learning tools to provide clinicians objective, accurate, and timely assessment of depression symptoms to assist with their clinical decision making process. Specifically, DepWatch collects sensory data passively from smartphones and wristbands, without any user interaction, and uses simple user-friendly interfaces to collect ecological momentary assessments (EMA), medication adherence and safety related data from patients. The collected data will be fed to machine learning models to be developed in the project to provide weekly assessment of patient symptom levels and predict the trajectory of treatment response over time. The assessment and prediction results are then presented using a graphic interface to clinicians to help them make critical treatment decisions. The main question the present clinical trial aims to answer are as follows: 1. Feasibility of the digital tool, DepWatch, to assist clinicians in depression treatment and inform their clinical decision process 2. Effectiveness of the digital tool, DepWatch, to improve depression treatment outcomes All study participants will carry the DepWatch app on their smartphones and wear a Fitbit provided by the study team during the study period. They will also complete brief questionnaires via the app at specific time intervals throughout the study period.

Primary Outcome

Study clinicians will complete surveys about feasibility and usability of the weekly. assessments provided to them on their patients in informing their clinical decision making process

Conditions Studied

Interventions

  • OTHER A mobile Health (mHealth) tool called 'DepWatch'

Study Locations (1)

Connecticut

  • University of Connecticut Health Center - Farmington

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2024-04-04
Est. Completion 2025-06-08
Phase NA
UConn Health

178 total trials

What the finished NCT06292221 record still lists

NCT06292221 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which A mobile Health (mHealth) tool called 'DepWatch' is the first listed.

NCT06292221 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT06292221 about?

NCT06292221 is a clinical study titled "Personalized Depression Treatment Supported by Mobile Sensor Analytics". The current best practice guidelines for treating depression call for close monitoring of patients, and periodically adjusting treatment as needed. This present study seeks to develop and investigate an innovative digital system, DepWatch, that leverages mobile health technologies and machine learni...

What is the current status of trial NCT06292221?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2024-04-04. Estimated completion is 2025-06-08.

What conditions does trial NCT06292221 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT06292221?

The interventions under investigation include: A mobile Health (mHealth) tool called 'DepWatch' (OTHER).

Who is sponsoring clinical trial NCT06292221?

This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06292221 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06292221's enrollment target sits among peer trials

22 605th of 679 higher than 74 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06292221, the US trial registry maintained by the National Library of Medicine. NCT06292221 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.